BTBD16

Across TCGA pan-cancer cohorts, BTBD16 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated BTBD16 data layer compared with 24 for mass-spec protein.

The strongest signal is observed in kidney chromophobe (KICH), where higher BTBD16 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated BTBD16 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

KICH, PRAD, and UCEC are the cancer types where BTBD16 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KICH	DFS	Median	All	0.102	0.848	.004	13	view →
PRAD	DFS	Median	All	0.120	0.777	<.001	12	view →
UCEC	DFS	Median	All	0.957	0.627	.026	10	view →
ACC	DFS	Median	All	0.140	0.666	.049	3	view →
SKCM	DFS	Median	IV	0.040	0.432	.038	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

BTBD16–KICH (DFS)

Open the KICH breakdown →